Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012

Evidence mounts for vitamin D multiple sclerosis role

Three studies published in Neurology add weight to the theory that vitamin D levels have an important effect on relapse rates and cerebral lesions in patients with multiple sclerosis.

20 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

Innate Immunotherapeutics today announced positive interim data from the company's Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).

18 Jun 2012

Study finds no evidence to support an effect of THC on MS progression

The first large non-commercial study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS) shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

16 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012

MRF announces achievement of myelin repair Phase 1 trial for MS

The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.

15 Jun 2012

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

A ten-year NIH-funded study has determined that a third of infants with prolonged seizures and fever suffer from either a new or reactivated roseola virus infection. Roseola viruses are the cause of the common childhood rash, but can also cause limbic encephalitis, a condition that frequently progresses to epilepsy. Investigators discovered one of the roseola viruses, human herpesvirus-6B (HHV-6B) in the blood of 32% of 169 infants with prolonged seizures, a condition known as status epilepticus.

15 Jun 2012

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012

EvaluatePharma releases World Preview 2018 report

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

14 Jun 2012

Billions of specific gut bacteria may play a role in autoimmune diseases

The billions of bugs in our guts have a newfound role: regulating the immune system and related autoimmune diseases such as rheumatoid arthritis, according to researchers at Mayo Clinic and the University of Illinois at Urbana-Champaign.

13 Jun 2012

Acorda commences AMPYRA clinical study for post-stoke deficits

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in a proof-of-concept study exploring the use of AMPYRA(dalfampridine) Extended Release Tablets, 10 mg in treating patients who have post-stroke deficits.

13 Jun 2012

Changes in walking speed in late life may signal MCI

A new study shows that changes in walking speed in late life may signal the early stages of dementia known as mild cognitive impairment (MCI).

12 Jun 2012

Updated AAN guideline outlines treatments for infantile spasms

The American Academy of Neurology has issued an updated guideline outlining the best treatments for infantile spasms, a rare type of seizure that can occur in infants and young children.

12 Jun 2012

IVF linked to increased relapse rate among MS patients

In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.

12 Jun 2012

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Genzyme, a Sanofi company, today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

12 Jun 2012

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."

12 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

Soy protein may not enhance overall cognitive ability in women

Contrary to earlier reports, a new study suggests that soy protein may not preserve overall thinking abilities in women over the age of 45, but may improve memory related to facial recognition.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012